Abstract | BAP1 is a deubiquitylase that is found associated with multiprotein complexes that regulate key cellular pathways, including the cell cycle, cellular differentiation, cell death, gluconeogenesis and the DNA damage response (DDR). Recent findings indicate that germline BAP1 mutations cause a novel cancer syndrome that is characterized, at least in the affected families that have been studied so far, by the onset at an early age of benign melanocytic skin tumours with mutated BAP1, and later in life by a high incidence of mesothelioma, uveal melanoma, cutaneous melanoma and possibly additional cancers.
For the past 15 years we have investigated a mesothelioma epidemic in Cappadocia, Turkey, where we have discovered that, in some families, susceptibility to mesothelioma, and possibly to mineral fibre carcinogenesis, is transmitted genetically in an autosomal dominant manner [1] [2] [3] [4] [5] . These studies have led us to search for a putative mesothelioma susceptibility gene (or genes). To isolate these putative genes, we worked with two unrelated US families, referred to as 'L' and 'W' for their Louisiana and Wisconsin residency, respectively, that experienced a high incidence of mesothelioma and that had only minimal potential exposure to asbestos 6 . Our first important clinical observation was that two members in one of these families developed uveal melanoma (UVM): one of them died of the disease and the other was treated at an early stage and cured, but subsequently developed mesothelioma 4, 6 . There are about 3,000 mesotheliomas and a similar or smaller number of UVMs diagnosed annually in the United States. The likelihood of both malignancies occurring in more than one individual in the same family was estimated to be 36 per trillion 6 ; this linkage suggested a common genetic denominator. Chromosome microarray and genetic linkage analyses on the L and W families implicated chromosome region 3p21 (REF. 6 ), a locus that is frequently altered in both UVM 7 and mesotheliomas 8, 9 . Sequencing this region of chromosome 3 led to the identification of BAP1 as the gene that was mutated and associated with high rates of mesothelioma in the L and W families (experiments are in progress to address whether BAP1 also causes the high incidence of mesothelioma in Cappadocia) 6 . BAP1 is a member of the ubiquitin C-terminal hydrolase (UCH) subfamily of deubiquitylating enzymes (DUBs) and was mutated in each family member who had developed mesothelioma, UVM and other cancers. None of these tumour types was detected in family members who did not carry BAP1 mutations 6 . Moreover, among several cases of sporadic mesotheliomas, we found that two of 26 patients had germline BAP1 mutations 6 and, importantly, we found that both of these patients had previously been diagnosed with UVM. None of the 24 patients with sporadic mesothelioma who had wild-type germline BAP1 had been diagnosed with UVM. On the basis of these findings, we have proposed that germline BAP1 mutations cause a new cancer syndrome that is characterized by mesothelioma and UVM 6 . In this Progress article, we discuss this potential inherited cancer syndrome, the possible mechanisms through which mutations in BAP1 might lead to tumour development and the clinical implications that are raised by the detection of germline BAP1 mutations.
Benign melanocytic tumours and BAP1
In parallel to our paper 6 , Wiesner et al. 10 reported that germline BAP1 mutations caused benign atypical melanocytic tumours. In a subsequent paper 11 , they noted that these melanocytic lesions histologically resembled "atypical Spitz tumours (ASTs)" (REF. 11 ). ASTs are a heterogeneous group of melanocytic tumours with overlapping histological characteristics between benign Spitz nevi and malignant melanoma, and they are formed by large melanocytes with mitotic activity not only in the superficial but also in the deep part of the lesion. They studied 32 sporadic ASTs and found that nine had loss of BAP1 expression and that eight of these had concomitant BRAF mutations. Only one of 23 ASTs that expressed BAP1 had a BRAF mutation (P < 0.0001) 11 . BRAF mutations are common in melanocytic nevi (80%) and in cutaneous melanoma (65%) but they are rare in ASTs 12 .
Njauw et al. 13 noted the same type of skin tumours arising in families with germline BAP1 mutations and referred to them as nevoid melanoma-like melanocytic proliferations (NEMMPs). Thus, pathologists have used different names to identify these pink-to tan-coloured skin tumours of about 0.2-1.0 cm in diameter, which macroscopically resemble dermal nevi. Together with a team of dermatologists, pathologists and dermatopathologists at three different US National Cancer Institute (NCI)-designated cancer centres we have reviewed the published morphology and histology of all of these melanocytic tumours, including some of the original tissue sections, which were kindly provided by Weisner and colleagues 10 .
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In addition, we examined the skin tumours that we detected in members of the L and W families. We found that all of the melanocytic tumours in these patients with mutant BAP1 had the same histological and molecular characteristics. In our review of the skin tumours in patients with mutant BAP1 we found that these are nevus-like lesions that are usually formed by a conventional junctional, compound or dermal nevus that is composed of small melanocytes expressing BAP1. Next to these conventional nevus cells there is a dermal lesion that is formed by large epithelioid BAP1-negative and most frequently BRAF-mutated melanocytes with almost no mitotic activity. This intradermal component with these unique features and the nearby conventional nevus-like lesion, to our minds, clearly sets these tumours apart from ASTs and other melanocytic lesions. Acknowledging that these lesions are characteristic of, although possibly not unique to, BAP1-mutation carriers, we proposed naming them melanocytic BAP1-mutated atypical intradermal tumours (MBAITs) 12 .
Malignant tumours in BAP1 families
Wiesner and colleagues noted that in the families that they had studied there was a possible increased risk of cutaneous melanoma and UVM 10 and they subsequently confirmed the association with mesothelioma in two of the three European families studied 14 . Such cancer clustering has been noted in other studies. A case report from 1972 described an individual who developed UVM, mesothelioma and meningioma 15 . Harbour et al. 7 reported inactivating mutations of BAP1 in 26 of 31 aggressive (class 2) UVMs, among which a germline mutation was found in one of the 26 patients 16 . Abdel-Rahman et al. 16 investigated BAP1 status in 53 unrelated patients with UVM who had a high risk of hereditary cancer. One of the 53 patients had a germline truncating BAP1 mutation that segregated in other family members. In this family, there were seven BAP1-mutation carriers (five tested and two inferred) and only one was cancer-free at the age of 55 years; the other six had developed UVM (two cases), cutaneous melanoma, mesothelioma, meningioma, lung and other types of carcinoma. The two patients treated for UVM subsequently developed a second malignancy 16 . Njauw et al. 13 sequenced BAP1 from 50 patients with metastatic UVM and from 50 patients with non-metastatic UVM. BAP1 was mutated in the germ line of 8% of patients with metastatic UVM: none of the patients with non-metastatic UVM had BAP1 germline mutations. They also found that two of the seven probands from families with UVM and cutaneous melanoma carried germline BAP1 mutations, compared with one of 193 probands from families with a history of cutaneous melanoma and no UVMs (P = 0.003). Aoude et al. 17 reported that two of 66 (3%) patients with UVM that were unselected for family history carried germline BAP1 mutations. Additional tumour types, including renal, breast and lung carcinomas were also found among BAP1-mutation carriers 6, 12, 13, 16 . BAP1 mutations have recently been reported in sporadic renal carcinoma 18 . Moreover, a novel inactivating germline splice mutation was reported in a family with UVM and cutaneous melanoma. Members of this family were also affected by multiple myeloma, paraganglioma and breast cancer 19 . 12 , indicate that mesothelioma, UVMs and cutaneous melanomas are clearly associated with the putative BAP1 cancer syndrome
. In addition, 35 BAP1 mutation carriers were investigated for the lesions that we call MBAITs, and 19 of these carriers were found to have one or more lesions (TABLE 1) . These benign skin lesions may occasionally progress to cutaneous melanoma 14 . In the BAP1-mutation families, there is an exceptionally high incidence of malignancy overall (69.74% cancer incidence among 76 mutation carriers). Some of these malignancies developed at an earlier age than that observed in the general population (TABLE 1) , as is expected in familial cancer syndromes. All of the mutation carriers unaffected by cancer are younger than 55 years old and may develop malignancies later in life. However, the relatively high frequency in the general population of the carcinomas that develop in BAP1 mutation carriers does not yet allow us to distinguish with certainty whether the association with carcinomas is causal. It should also be noted that population-based studies have shown that mutation carriers in the general population may have a lower risk than that suggested by estimates obtained from families with multiple tumours, as is observed, for example, for CDKN2A mutations 20 .
Therefore, large population-based studies will be required to validate the association of germline BAP1 mutations with the exceptionally high incidence of malignancies detected in the BAP1-mutant families.
Most autosomal dominant cancer syndromes cause tumours in specific sites and tissues, and do not result in an overall increase in cancer risk. However, Li-Fraumeni syndrome, which is caused by inherited mutations of the TP53 tumour suppressor gene, is an autosomal dominant cancer syndrome that is characteristically associated with the development of multiple tumour types 21 . Is the BAP1 cancer syndrome, similar to the Li-Fraumeni syndrome, associated with an overall general increase in cancer risk? If so, why do mesotheliomas, UVMs and cutaneous melanomas predominate? As we expand our studies to include additional families that have mutant BAP1 genes we will address these questions. We discuss below the putative functions of BAP1 and how they might contribute to cancer. Most data about BAP1 function have been published in the past 2 years, following a renewed interest in this gene that was caused by the discovery of its association with human mesothelioma and melanomas, and possibly with other cancer types. Therefore, some of the most recent studies have still to be independently verified. Overall, the data indicate that BAP1 can influence multiple cellular pathways, at times suppressing and at times promoting cell growth, possibly in a cell type-and species-specific manner.
BAP1 has multifaceted functions
Protein ubiquitylation was initially seen as a mechanism to label proteins for degradation; however, this idea has evolved as we have come to understand that ubiquitylation and DUBs regulate various cellular processes, including DNA repair, gene transcription, cell membrane trafficking, cell cycle progression, stress response, cell communication, differentiation and apoptosis, and that they have a role in cancer development 22, 23 . BAP1 is located at chromosome region 3p21.1 (REF. 24 ), a genomic region that is deleted in several human malignancies, including in approximately 30-60% of mesotheliomas 6, 8, 9, 25 and 85% of metastasizing UVMs 10 . BAP1 was discovered in a yeast two-hybrid screen owing to its interaction with the RING finger domain of the tumour suppressor BRCA1. Initial data suggested that BAP1 was a tumour suppressor gene because BAP1 suppressed the growth of MCF7 human breast cancer cells in soft agar 24 . However, despite the fact that autoubiquitylated BRCA1 is a DUB substrate, subsequent experiments have shown that BAP1 does not influence the deubiquitylation of BRCA1 (REF. 26 ). BRCA1 forms a heterodimer through its RING domain with BRCA1-associated RING domain 1 (BARD1), and this BRCA1-BARD1 tumoursuppressor complex has E3 ubiquitin ligase activity that regulates the DNA damage response (DDR) 27 . BAP1 binds and deubiquitylates BARD1, thus modulating the E3 ligase activity of BRCA1-BARD1 (REF. 28 ). Indeed, inhibition of BAP1 by short hairpin RNAs (shRNAs) impaired the DDR and caused HeLa cells to become hypersensitive to ionizing radiation, resulting in S phase retardation, a phenotype that is similar to BRCA1 deficiency. Therefore, BRCA1-mediated ubiquitylation and BAP1-mediated deubiquitylation may coordinately regulate these cellular processes 28 .
Ventii et al. reported that in human NCI-H226 non-small-cell lung cancer cells that do not express BAP1, its exogenous expression through lentivirus infection accelerated passage through the G1/S checkpoint. This effect might have impaired DNA repair, leading to DNA damage and to the induction of cell death both by apoptosis and by necrosis 29 . Accordingly, NCI-H226 cells expressing exogenous wild-type BAP1 grew poorly in cell culture and, when injected into athymic nude mice, they formed tumours that were about 10-15-fold smaller than those obtained with cells infected with vector alone or those expressing BAP1 mutants lacking deubiquitylating activity (C91A substitution) or the second nuclear localization signal, NLS2 (which is required for the nuclear compartmentalization of BAP1) 29 . BAP1-mediated growth suppression in this in vivo model was BRCA1-independent. These data were interpreted as further evidence that BAP1 is a tumour suppressor gene, and that both nuclear localization and deubiquitylating activity are required for BAP1-mediated tumour suppressor activity 29 . When in the nucleus, BAP1 interacts with several proteins, including host cell factor 1 (HCF1; also known as HCFC1). HCF1 is a cell cycle regulator that contains a Kelch domain that binds to a conserved peptide sequence that is known as the HCF1-binding motif (HBM) and that is common to several transcription factors. Although HCF1 does not bind DNA directly, transcription factors that contain a HBM domain recruit HCF1 to specific promoters, where it regulates transcription. HCF1 binds BAP1 through a HBM sequence present in the middle portion of BAP1 (REFS 30, 31) . HCF1 is ubiquitylated on lysine residues, preferentially through K48-linked and K63-linked chains. BAP1 hydrolyses K48-linked chains 30, 31 . Overexpression of mutated, catalytically inactive BAP1 (REF. 30 ) and BAP1 silencing 31 resulted in a modest accumulation of HCF1, indicating that HCF1 K48 ubiquitylation does not necessarily label HCF1 for degradation.
A crucial role of HCF1 is to sustain the formation of complexes between chromatinmodifying enzymes and transcription factors. For example, by recruiting histone methyltransferases to the E2F1 transcription factor, HCF1 allows the transcription of E2F1 target genes, including genes that control the cell cycle and cellular proliferation 32 . It has been proposed that ubiquitylation of HCF1 blocks E2F-responsive promoter activity, and that HCF1 deubiquitylation by BAP1 would remove this inhibition and promote cell proliferation 33 . In addition, co-immunoprecipitation experiments have shown that BAP1 directly associates with E2F family members, suggesting a possible additional direct control of these transcriptional factors by BAP1 (REF. 33 ). Therefore, the ability of BAP1 to influence progression through the cell cycle may be mediated, at least in part, by E2F family members 33 . The Drosophila melanogaster Polycomb group (PcG) gene calypso is homologous to the human BAP1 gene. PcG proteins are transcriptional repressors that control cellular differentiation and development 34 . These proteins form multiprotein complexes that bind to chromatin and together repress gene expression. The two main families of PcG protein complexes are Polycomb repressive complex 1 (PRC1) and PRC2. Compaction of nucleosomes and ubiquitylation of histone 2A (H2A) are two of the mechanisms through which PRC1 silences gene expression 35 . Monoubiquitylation of H2A is a crucial mechanism in the control of transcription initiation and elongation, transcription silencing and DNA repair 36 . In D. melanogaster, CALYPSO binds additional sex combs (ASX) to form the Polycomb repressive deubiquitylase (PR-DUB) complex that specifically removes monoubiquitin from H2A. Similarly, in humans, BAP1 binds ASXL1 through its carboxyl terminus and deubiquitylates H2A 34 . It seems to be possible that PR-DUB may help to fine-tune gene expression levels by preventing the hyperubiquitylation of H2A by PRC1 and BRCA1. BRCA1 maintains the ubiquitylated status of H2A, a mechanism that is crucial for BRCA1 tumour suppressor activity because it antagonizes the transcriptional derepression of satellite DNA repeats that contribute to breast cancer growth 37 . Thus, PcG activity may not simply be ascribed to its gene suppressive functions, but may rather result from the delicate balance between H2A ubiquitylation by PRC1 and BRCA1 (which suppress transcription), and H2A deubiquitylation by PR-DUB (which should re-activate transcription). PRC2 might also be important in tumours that have mutant BAP1. The PRC2 proteins EZH2 and EED are frequently overexpressed in mesothelioma, and Kemp et al. proposed inhibiting PRC2 as a possible therapeutic strategy for treating mesothelioma 38 . Yu et al. 39 reported that almost all cellular BAP1 is found in high-molecularweight multiprotein complexes, which include HCF1, ASXL1 and ASXL2, O-linked N-acetylglucosamine transferase (OGT) and the forkhead transcription factors Forkhead box K1 (FOXK1) and FOXK2, and which they called the BAP1 core complex (FIG. 1a) . This core complex, in turn, associates with additional regulators and transcription factors to form specific functional complexes that may be cell type specific 39 . In addition, recent studies have shown that BAP1, HCF1 and OGT (which is essential for Polycombmediated gene repression in D. melano gaster 40 ) exist as a multiprotein complex that regulates itself and that also regulates several targets (FIG. 1b) . For example, BAP1 deubiquitylates and thus stabilizes OGT, which O-GlcNacylates HCF1 and activates it 41, 42 . Activated HCF1 recruits OGT to O-GlcNacylate peroxisome proliferator activator receptor-γ co-activator 1α (PGC1α). This modification enables BAP1 to bind and deubiquitylate PGC1α, which is stabilized and can promote gluconeogenesis 42 (FIG. 1b) . Moreover, chromatin immunoprecipitation (ChIP) assays identified a total of 9,128 BAP1 peaks (5,926 located near the transcription start sites of 5,731 genes); 85% of promoters occupied by BAP1 also contained HCF1, and BAP1, HCF1 and OGT were recruited as a complex on 1,827 different promoters 41 . BAP1 has also been shown to form a ternary complex with HCF1 and the transcription factor Yin Yang 1 (YY1) that controls the transcription of genes involved in cell proliferation. Specifically, BAP1 interacts with the zinc fingers of YY1 through its coiled-coil motif and it is recruited together with HCF1 to the promoter of COX7C that encodes a component of the mitochondrial respiratory chain 39 . Thus, it can be expected that BAP1 influences a wide array of cellular functions, and consistent with this hypothesis, BAP1 depletion by RNA inhibition induced significant changes in the expression of many genes that control various cellular pathways 39 . In summary, despite the findings implicating BAP1 in the suppression of proliferation 24, 29 , some groups have reported that BAP1 promotes cell proliferation 25, 30, 33 . These conflicting results suggest that BAP1 effects may be cell type specific and/or that they
Box 1 | Clinical considerations
Wiesner et al. 10 noted that in BAP1-mutation carriers benign melanocytic tumours develop during the second decade of life and that their number increases with age, a finding that has been confirmed in the BAP1-mutant families that we are studying 12 . The occurrence of cutaneous melanoma in some BAP1-mutation carriers, including one that appeared to originate from these melanocytic tumours 14 , suggests that these benign tumours occasionally undergo malignant transformation. This finding may account, at least in part, for the overall high risk of cutaneous melanoma detected among BAP1 germline mutation carriers (TABLE 1) . We propose that these melanocytic tumours, which we term melanocytic BAP1-mutated atypical intradermal tumours (MBAITs) 12 , could be viewed as a specific phenotypic marker of BAP1-mutation carriers. Other autosomal dominant cancer syndromes also have phenotypic markers, such as adenomas in familial adenomatous polyposis families, as well as Lisch nodules and café-au-lait spots in families with neurofibromatosis type 1. Suspected MBAITs could be removed and tested to identify patients with BAP1 mutations. If this approach was found to have clinical relevance it could allow for the close monitoring of these individuals and might enable the early detection of cutaneous melanoma, uveal melanoma (UVM), mesothelioma and possibly other cancers 12 . Both cutaneous melanoma and UVM can be cured when detected at an early stage but are fatal when they have metastasized. Early diagnosis also benefits patients with mesothelioma because when they are diagnosed and treated at a very early stage, survival for 5 or more years is not uncommon 12, 49 . Thus, the detection of families with inherited mutations of BAP1 offers opportunities for early cancer detection and more effective therapeutic approaches. could be influenced by the experimental approach used. BAP1 activity could vary in different cells because the BAP1 core complex 39 is likely to associate with different transcription factors and thus influence different pathways in a cell type-specific manner. Also, some of the proteins that normally bind BAP1 may have different activities in its absence. For example, YY1 acts as a repressor or as an activator of COX7C depending on whether it is bound to the BAP1-HCF1 complex 39 . All the germline mutations found in the BAP1 cancer syndrome encode BAP1 proteins lacking the nuclear localization sequence, and most of them have an intact UCH domain (FIG. 2) . In the tumours that develop in BAP1-mutant carriers, BAP1 expression is absent either because of loss of heterozygosity (LOH), resulting in biallelic inactivation, or because the BAP1 protein is localized in the cytoplasm 6, 16 where it may retain DUB activity, with as yet unknown possible effects on the cellular 'ubiquitinome' .
What do BAP1-associated cancers share? Because germline BAP1 mutations are associated with mesotheliomas, UVMs and cutaneous melanomas, there should be some common pathways controlled by BAP1 that are of particular importance to the development of these malignancies. The finding that somatic BAP1 mutations are common in these cancers supports this interpretation.
Somatic BAP1 mutations were found in 84% of metastasizing UVM biopsy samples 7 , as well as in 22% 6 and 23% 25 of sporadic US mesothelioma biopsy samples. By contrast, Yoshikawa et al. found somatic inactivating BAP1 mutations in 61% of Japanese mesothelioma biopsy samples 43 . To address this discrepancy, in collaboration with our Japanese colleagues, we are currently investigating whether the higher incidence of BAP1 mutations that they detected was caused by ethnic differences or by the different technical approach used; that is, multiplex ligation-dependent probe amplification (MLPA) 43 compared with PCR 6 .
Studies in mice 41 revealed that Bap1 deletion is lethal during embryogenesis. When Bap1 was deleted in adult mice that expressed the tamoxifen-inducible recombinase Cre-ERT2 ubiquitously and that had Bap1 exons 4 and 5 flanked by Lox sites, these mice developed splenomegaly caused by extramedullary haematopoiesis, monocytosis, neutrophilia and progressive anaemia 41 , findings that are comparable to the human myelodysplastic syndrome (MDS). The absence of mesothelioma, uveal and cutaneous melanoma in these mice is somewhat puzzling, and may be related to species differences. In addition, at the level of disease causation, the common denominator among mesotheliomas and melanomas is a well-defined role of environmental carcinogens. We are currently testing the hypothesis that germline Bap1 mutations increase the susceptibility to mineral fibreinduced and ultraviolet (UV) light-induced carcinogenesis; this may explain the absence of mesothelioma and melanoma in mice that were not exposed to these carcinogens. Mineral fibres are well-documented causes . Other putative BAP1 partners are shown in grey. It is possible that BAP1, HCF1, Ying Yang 1 (YY1) and OGT might also be part of one large protein complex. Third, a BAP1-HCF1-OGT complex has been shown to increase the stability of peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α), regulating gluconeogenesis and possibly mitochondrial biogenesis 42 . BARD1, BRCA1-associated RING domain protein 1; CBXs, mammalian chromobox protein homologues; EZHs, enhancer of zeste homologues; FOXK1, Forkhead box protein K1; HAT1, histone acetyltransferase 1; KDM1B, lysine-specific demethylase 1B; PCLs, Polycomb-like proteins; RNF2, RING finger protein 2. [1] [2] [3] [4] [5] . The deposition of these fibres in tissues induces a chronic inflammatory reaction that is started by the release of high mobility group box 1 (HMGB1) by mesothelial cells undergoing programmed cell necrosis 2, 44 . Extracellular HMGB1 starts the inflammatory process by recruiting macrophages and other immune cells that in turn actively secrete HMGB1 and other cytokines, and release mutagenic oxygen and nitric radicals, promoting carcino genesis and mesothelioma growth (reviewed in REF. 2 ). In such an environment, an impaired DDR caused by BAP1 deletion might be expected to favour the accumulation of genetic damage that eventually gives rise to a malignant clone. However, Bott et al. 25 found no consistent differences in RAD51 or BRCA1 complex formation between BAP1 wild-type and BAP1-deficient cell lines exposed to ionizing radiation, suggesting no crucial role for BAP1 in the formation of these DNA repair complexes. Moreover, we 6 found minimal, and Wiesner et al.
14 found no, evidence of exposure to asbestos or erionite among the patients who developed mesothelioma in the families with BAP1 mutations, findings that do not support gene-environment interaction causing mesothelioma, at least in these families. A separate mechanism, by which HMGB1 might influence mesothelioma especially in cells lacking BAP1, is the capacity of HMGB1 to induce nucleosome assembly 45 . High levels of HMGB1 may increase gene repression by PRC1 in a mutated BAP1 background.
UV light exposure increases the risk of cutaneous melanoma. The role of UV light exposure in causing UVM is still debated 46 ; however, it seems possible that BAP1-mutation carriers are at an increased risk because of impaired DDR. Because BAP1-mutation carriers represent only a small proportion of patients who develop UVM (3-4%) 13, 17 , the overall association of UVM with UV light exposure should be re-evaluated in BAP1 mutation-positive versus BAP1 mutation-negative patients.
Moreover, BAP1 is a UV-inducible substrate of the ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) kinases. ATM and ATR regulate the DNA damage checkpoint that inhibits cell cycle progression in response to genomic insults -such as UV -to allow time to damage repair or, if the damage cannot be repaired, to enter apoptosis 47 . We anticipate that as more studies uncover the precise mechanisms by which BAP1 mutations cause mesothelioma and melanomas, specific preventive and therapeutic approaches for these malignancies will be developed
. It is worth noting that a recent paper showed that histone deacetylase inhibitors (HDACIs) impair the in vitro and in vivo growth of UVM metastatic tumours with BAP1-inactivating mutations 48 . Specifically, HDAC inhibitors block H2A ubiquitylation through the inhibition of PRC1 and so reverse H2A hyperubiquitylation that is caused by BAP1 loss. HDACIs also induce the differentiation of class 2 UVM to class 1 UVM 48 , which is less aggressive.
Conclusions
The apparent ability of BAP1 mutations to cause multiple tumour types and the high tumour phenotype penetrance (TABLE 1) suggests that this gene has a major role in influencing cancer cell growth. The pleiotropic effects of BAP1 can account for this finding. Not only is BAP1 the human homologue of the D. melanogaster PcG gene calypso, but it also contains a HBM domain, which is absent in CALYPSO, that allows BAP1 to bind HCF1, a chromatin-associated protein that similar to PcG regulates the expression of a plethora of different The clinical implications of these recent findings have yet to be fully established 12 . The presence of specific skin lesions that we have called MBAITs is an important clinical feature that might help identify BAP1-mutation carriers. We think that these patients require close monitoring for early detection and curative resection of uveal and cutaneous melanoma, and of mesothelioma and other malignancies.
